Waldenström's macroglobulinemia
- PMID: 12240489
- DOI: 10.1188/02.CJON.283-286
Waldenström's macroglobulinemia
Abstract
Waldenström's macroglobulinemia (WM) is a rare monoclonal gammopathy. Its clinical signs and symptoms include fatigue, weakness, hepatomegaly, splenomegaly, lymphadenopathy, and neuropathies. Patients with WM have a circulating tumor marker, the monoclonal immunoglobulin M protein. High levels of this protein can produce hyperviscosity syndrome, which often is characterized by bleeding from the mucous membranes of the nose and mouth. Asymptomatic patients with WM usually are not treated. Treatment of symptomatic patients and patients with relapsed WM may include alkylating agents, particularly chlorambucil; purine nucleoside analogs, such as fludarabine and cladribine; and, most recently, the use of rituximab. With knowledge about this unusual disease, oncology nurses can provide better care and education for patients with WM.
Similar articles
-
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.Semin Oncol. 2003 Apr;30(2):121-6. doi: 10.1053/sonc.2003.50039. Semin Oncol. 2003. PMID: 12720120 Review.
-
Waldenström's macroglobulinemia.Oncologist. 2000;5(1):63-7. doi: 10.1634/theoncologist.5-1-63. Oncologist. 2000. PMID: 10706651 Review.
-
Rituximab-based treatments in Waldenström's macroglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Clin Lymphoma Myeloma. 2009. PMID: 19362975 Review.
-
Diagnosis and management of Waldenstrom's macroglobulinemia.J Clin Oncol. 2005 Mar 1;23(7):1564-77. doi: 10.1200/JCO.2005.03.144. J Clin Oncol. 2005. PMID: 15735132 Review.
-
Fludarabine in Waldenstrom's macroglobulinemia.Semin Oncol. 2003 Apr;30(2):239-42. doi: 10.1053/sonc.2003.50040. Semin Oncol. 2003. PMID: 12720144 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
